Edition:
United States

Aviragen Therapeutics Inc (AVIR.OQ)

AVIR.OQ on NASDAQ Stock Exchange Capital Market

0.59USD
1:05pm EST
Change (% chg)

$-0.00 (-0.34%)
Prev Close
$0.59
Open
$0.59
Day's High
$0.59
Day's Low
$0.58
Volume
6,372
Avg. Vol
97,205
52-wk High
$1.48
52-wk Low
$0.44

Chart for

About

Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its... (more)

Overall

Beta: -0.07
Market Cap(Mil.): $22.78
Shares Outstanding(Mil.): 38.65
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Aviragen Therapeutics Completes Patient Enrollment In Phase 2 Clinical Trial For Condyloma Treatment

* AVIRAGEN THERAPEUTICS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF TESLEXIVIR (BTA074) FOR THE TREATMENT OF CONDYLOMA

Nov 29 2017

BRIEF-SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics is superior to Vaxart's proposed transaction

* SC Fundamental Value Fund LP says ‍​believes that liquidation of Aviragen Therapeutics Inc is superior to Vaxart Inc's proposed transaction - SEC Filing

Nov 09 2017

BRIEF-Aviragen Therapeutics Q1 loss per share $0.14

* Aviragen Therapeutics reports first quarter of fiscal year 2018 financial results

Nov 02 2017

BRIEF-Aviragen Therapeutics to pay Vaxart $1.95 mln, if deal terminated

* On termination of merger under specified circumstances, co required to pay Vaxart termination fee of $1.95 million ​- SEC filing

Oct 30 2017

BRIEF-Aviragen Therapeutics and Vaxart enter into merger agreement

* Aviragen Therapeutics and Vaxart enter into merger agreement

Oct 30 2017

BRIEF-Aviragen Therapeutics reports Q4 loss per share $0.15

* Aviragen therapeutics reports fourth quarter and fiscal year 2017 financial results

Aug 31 2017

BRIEF-SC Fundamental Value Fund LP reports 5.01 pct stake in Aviragen Therapeutics Inc as of June 21

* SC Fundamental Value Fund Lp reports 5.01 percent stake in Aviragen Therapeutics Inc as of June 21 - SEC filing Source text - (http://bit.ly/2tsaxus) Further company coverage:

Jun 30 2017

Earnings vs. Estimates